Merit Financial Group LLC Has $4.37 Million Stock Holdings in Sanofi $SNY

Key Points

• Merit Financial Group LLC has increased its holdings in Sanofi by 224.8% during the 2nd quarter, now owning 90,455 shares valued at $4.37 million.
• Sanofi reported earnings per share (EPS) of $0.90 for the last quarter, missing the consensus estimate of $0.96, with revenue of $11.34 billion exceeding expected levels.
• Sanofi currently has a market capitalization of $122.06 billion and holds a consensus rating of "Buy" among analysts, with an average price target of $62.67.

Merit Financial Group LLC boosted its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 224.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 90,455 shares of the company's stock after buying an additional 62,607 shares during the period. Merit Financial Group LLC's holdings in Sanofi were worth $4,370,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cardinal Capital Management lifted its position in Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after acquiring an additional 199 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares in the last quarter. Capital Analysts LLC boosted its position in shares of Sanofi by 14.0% during the first quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock worth $92,000 after buying an additional 204 shares during the period. Thomasville National Bank grew its holdings in shares of Sanofi by 0.3% during the second quarter. Thomasville National Bank now owns 80,440 shares of the company's stock worth $3,886,000 after buying an additional 211 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC raised its position in Sanofi by 1.0% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 24,114 shares of the company's stock valued at $1,337,000 after buying an additional 232 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of SNY opened at $49.71 on Tuesday. The company has a market cap of $122.06 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.24 and a beta of 0.51. The firm has a 50-day moving average of $48.20 and a 200-day moving average of $49.93. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter last year, the business posted $1.73 earnings per share. The company's revenue for the quarter was down 7.0% on a year-over-year basis. As a group, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Sanofi in a research report on Saturday, September 27th. Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Finally, Morgan Stanley upgraded Sanofi from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Sanofi has a consensus rating of "Buy" and an average price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.